GHP Q1 2018

2 GHP / Q1 2018 Editor’s Note , Welcome to the first issue of GHP Magazine for 2018, your source for the latest news and exciting features in the healthcare and pharmaceutical industries. In this month’s issue, we look at how the Alliance for Safe Biologic Medicines (ASBM) has recently announced that it has developed a web-based tool for the naming of biologic medicines to quickly ensure compliance with naming standards set forth by the FDA and World Health Organization (WHO). The tool, called “SuffixAudit”, will be made available to regulators and manufacturers. Also in recent news, the latest Healthtech M&A Report from international technology mergers and acquisitions advisors, Hampleton Partners, has revealed how the ‘perfect storm’ of rapidly converging digital technologies and societal changes, coupled with the entrance of tech giants, such as Amazon into the healthcare and medical systems market, is driving intense innovation and M&A activity in the Healthtech sector. Elsewhere in this edition, one of the largest plastics, chemicals and refining companies in the world, LyondellBasell is bringing to market the new Purell RP375R - a polypropylene (PP) random copolymer that delivers excellent resistance to gamma and X-ray radiation sterilisation. Finally, over the past two decades, Harley Street Clinic Founder & Skin Expert, Zaheda Hafez has been inspired by her clients that she has advised at her award-winning firm. Utilising her expertise to create Zaheda Skincare, in collaboration with leading cosmetic scientists, We profile the product and examine what makes it so successful. Here at GHP Magazine, we hope that you thoroughly enjoy reading this edition and look forward to hearing from you. Jessie Daykin, Editor Phone: +44 (0) 203 725 6842 Email: [email protected] Website: AI Global Media, Ltd. (AI) takes reasonable measures to ensure the quality of the information on this web site. However, AI will not assume any legal liability or responsibility for the accuracy, correctness or completeness of any information that is available through this web site. If errors are brought to our attention, we will try to correct them. The information available through the website and our partner publications is for your general information and use and is not intended to address any particular finance or investment requirements. In particular, the information does not constitute any form of advice or recommendation by us or any of our partner publications and is not intended to be relied upon by users in making or refraining from making any investment or financial decisions. Appropriate independent advice should be obtained before making any such decision. Any arrangement made between you and any third party named in the site is at your sole risk and responsibility.